Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib with IDH inhibitors in IDH-mutated MPNs
NCT04955938Phase 1Withdrawn
- Sponsor
- University of Chicago
- Start
- Oct 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fedratinib in Myeloproliferative Neoplasm (MPN), sponsored by University of Chicago. Planned start Oct 2021; status: withdrawn.
02
Drugs
fedratinib
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04955938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955938.